Intercept price target raised to $525 from $360 at Oppenheimer Oppenheimer increased its price target on Intercept after updating its valuation estimate of the company's OCA drug after positive data for the drug was reported. The firm thinks the stock could rise further as investors focus on potentially positive upcoming fibrosis data. Oppenheimer keeps an Outperform rating on the shares.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.